Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Genomic Health, Inc.: Still Waiting for Reimbursement


Genomic Health, Inc.: Still Waiting for Reimbursement

Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net loss, moving the company closer to its goal of being profitable for the entire year.

Metric

Q2 2017

Continue reading


Source: Fool.com

Genomic Health Stock

€57.72
-2.270%
We can see a decrease in the price for Genomic Health. Compared to yesterday it has lost -€1.340 (-2.270%).

Like: 0
Share

Comments